ExpreS2ion Biotechnologies contributes to scientific article
ExpreS2ion Biotechnologies’ scientists contributed to the research for the article by Thrane et al, ”Bacterial superglue enables easy development of […]
We’re Here To Solve Your Biggest Protein Challenges
ExpreS2ion Biotechnologies’ scientists contributed to the research for the article by Thrane et al, ”Bacterial superglue enables easy development of […]
The talk titled “Development of Drosophilia S2 based sub-unit antigen vaccine production processes” will be held on Day 1 (Monday, […]
The meeting features the most exciting and challenging discussions on the industry’s most difficult applications including viral gene vectors and […]
Edited by Robert W. Sauerwein and Thomas L. Richie Access the journal issue here: http://www.sciencedirect.com/science/journal/0264410X/33/52 Articles citing the use of ExpreS2: […]
BioEurope 2015 November 2–4, 2015, Munich, Germany http://www.ebdgroup.com/bioeurope/media/about_conf.php Is your project being slowed down by protein manufacturing challenges? Try ExpreS2, […]
The execution with Boston Children’s Hospital, located in Boston, Massachusetts, USA, of a non-exclusive research license agreement to use ExpreS2ion’s […]
March 2015 A vaccine against placental malaria made with ExpreS2ion® Biotechnologies protein expression technology, ExpreS2, is ready to start human […]
ExpreS2ion Biotechnologies is licensed to Cancer Research UK’s Protein Purification Facility. Read the PR
EU funding for clinical trials of a placental malaria vaccine. Read the PR
ExpreS2ion Biotechnologies, Mucosis, and University of Copenhagen receive Eurostars grant for the pre-clinical development of an innovative placental malaria vaccine. […]